Lidia Glodzik1, Marc Sollberger2, Achim Gass3, Amit Gokhale4, Henry Rusinek4, James S Babb4, Jochen G Hirsch3, Michael Amann3, Andreas U Monsch5, Oded Gonen4. 1. Department of Radiology, New York University School of Medicine, New York, NY, USA Department of Psychiatry, New York University School of Medicine, New York, NY, USA. 2. Department of Neurology and Neuroradiology, University Hospital Basel, Basel, Switzerland Department of Geriatrics, University Hospital Basel, Basel, Switzerland. 3. Department of Neurology and Neuroradiology, University Hospital Basel, Basel, Switzerland. 4. Department of Radiology, New York University School of Medicine, New York, NY, USA. 5. Department of Geriatrics, University Hospital Basel, Basel, Switzerland.
Abstract
BACKGROUND: Mild cognitive impairment (MCI) is an intermediary state on the way to Alzheimer's disease (AD). Little is known about whole brain concentration of the neuronal marker, N-acetylaspartate (NAA) in MCI patients. OBJECTIVE: To test the hypothesis that since MCI and AD are both neurodegenerative, quantification of the NAA in their whole brain (WBNAA) could differentiate them from cognitively-intact matched controls. METHODS: Proton MR spectroscopy to quantify the WBNAA was applied to 197 subjects (86 females) 72.6 ± 8.4 years old (mean ± standard deviation). Of these, 102 were cognitively intact, 42 diagnosed as MCI, and 53 as probable AD. Their WBNAA amounts were converted into absolute concentration by dividing with the brain volume segmented from the MRI that also yielded the fractional brain volume (fBPV), an atrophy metric. RESULTS: WBNAA concentration of MCI and AD patients (10.5 ± 3.0 and 10.1 ± 2.9 mM) were not significantly different (p = 0.85). They were, however, highly significantly 25-29% lower than the 14.1 ± 2.4 mM of normal matched controls (p < 10-4). The fBPV of MCI and AD patients (72.9 ± 4.9 and 69.9 ± 4.7%) differed significantly from each other (4%, p = 0.02) and both were significantly lower than the 74.6 ± 4.4% of normal elderly (2%, p = 0.003 for MCI; 6%, p < 10-4 for AD). ROC curve analysis has shown WBNAA to have 70.5% sensitivity and 84.3% specificity to differentiate MCI or AD patients from normal elderly versus just 68.4 and 65.7% for fBPV. CONCLUSION: Low WBNAA in MCI patients compared with cognitively normal contemporaries may indicate early neuronal damage accumulation and supports the notion of MCI as an early stage of AD. It also suggests WBNAA as a potential marker of early AD pathology.
BACKGROUND: Mild cognitive impairment (MCI) is an intermediary state on the way to Alzheimer's disease (AD). Little is known about whole brain concentration of the neuronal marker, N-acetylaspartate (NAA) in MCI patients. OBJECTIVE: To test the hypothesis that since MCI and AD are both neurodegenerative, quantification of the NAA in their whole brain (WBNAA) could differentiate them from cognitively-intact matched controls. METHODS: Proton MR spectroscopy to quantify the WBNAA was applied to 197 subjects (86 females) 72.6 ± 8.4 years old (mean ± standard deviation). Of these, 102 were cognitively intact, 42 diagnosed as MCI, and 53 as probable AD. Their WBNAA amounts were converted into absolute concentration by dividing with the brain volume segmented from the MRI that also yielded the fractional brain volume (fBPV), an atrophy metric. RESULTS: WBNAA concentration of MCI and ADpatients (10.5 ± 3.0 and 10.1 ± 2.9 mM) were not significantly different (p = 0.85). They were, however, highly significantly 25-29% lower than the 14.1 ± 2.4 mM of normal matched controls (p < 10-4). The fBPV of MCI and ADpatients (72.9 ± 4.9 and 69.9 ± 4.7%) differed significantly from each other (4%, p = 0.02) and both were significantly lower than the 74.6 ± 4.4% of normal elderly (2%, p = 0.003 for MCI; 6%, p < 10-4 for AD). ROC curve analysis has shown WBNAA to have 70.5% sensitivity and 84.3% specificity to differentiate MCI or ADpatients from normal elderly versus just 68.4 and 65.7% for fBPV. CONCLUSION: Low WBNAA in MCI patients compared with cognitively normal contemporaries may indicate early neuronal damage accumulation and supports the notion of MCI as an early stage of AD. It also suggests WBNAA as a potential marker of early AD pathology.
Entities:
Keywords:
Alzheimer's disease; N-acetylaspartate; magnetic resonance spectroscopy; mild cognitive impairment; normal aging
Authors: M J de Leon; A Convit; O T Wolf; C Y Tarshish; S DeSanti; H Rusinek; W Tsui; E Kandil; A J Scherer; A Roche; A Imossi; E Thorn; M Bobinski; C Caraos; P Lesbre; D Schlyer; J Poirier; B Reisberg; J Fowler Journal: Proc Natl Acad Sci U S A Date: 2001-08-28 Impact factor: 11.205
Authors: P Fischer; S Jungwirth; S Zehetmayer; S Weissgram; S Hoenigschnabl; E Gelpi; W Krampla; K H Tragl Journal: Neurology Date: 2007-01-23 Impact factor: 9.910
Authors: L L Chao; N Schuff; J H Kramer; A T Du; A A Capizzano; J O'Neill; O M Wolkowitz; W J Jagust; H C Chui; B L Miller; K Yaffe; M W Weiner Journal: Neurology Date: 2005-01-25 Impact factor: 9.910
Authors: M Catani; A Cherubini; R Howard; R Tarducci; G P Pelliccioli; M Piccirilli; G Gobbi; U Senin; P Mecocci Journal: Neuroreport Date: 2001-08-08 Impact factor: 1.837
Authors: Lidia Glodzik-Sobanska; Henry Rusinek; Lisa Mosconi; Yi Li; Jiong Zhan; Susan de Santi; Antonio Convit; Kenneth Rich; Miroslaw Brys; Mony J de Leon Journal: Neuroimaging Clin N Am Date: 2005-11 Impact factor: 2.264
Authors: A Falini; M Bozzali; G Magnani; G Pero; A Gambini; B Benedetti; R Mossini; M Franceschi; G Comi; G Scotti; M Filippi Journal: Neuroimage Date: 2005-07-15 Impact factor: 6.556
Authors: F W Unverzagt; S Gao; O Baiyewu; A O Ogunniyi; O Gureje; A Perkins; C L Emsley; J Dickens; R Evans; B Musick; K S Hall; S L Hui; H C Hendrie Journal: Neurology Date: 2001-11-13 Impact factor: 9.910
Authors: Jean-Pierre Dollé; Jeffrey M Rodgers; Kevin D Browne; Thomas Troxler; Feng Gai; Douglas H Smith Journal: Neurobiol Dis Date: 2018-05-31 Impact factor: 5.996
Authors: Eva Widerström-Noga; Varan Govind; James P Adcock; Bonnie E Levin; Andrew A Maudsley Journal: J Neurotrauma Date: 2016-01-15 Impact factor: 5.269
Authors: Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber Journal: World J Biol Psychiatry Date: 2017-10-27 Impact factor: 4.132
Authors: Giuseppe Paglia; Matteo Stocchero; Stefano Cacciatore; Steven Lai; Peggi Angel; Mohammad Tauqeer Alam; Markus Keller; Markus Ralser; Giuseppe Astarita Journal: J Proteome Res Date: 2016-01-12 Impact factor: 4.466
Authors: Artur M N Coutinho; Fábio H G Porto; Poliana F Zampieri; Maria C Otaduy; Tíbor R Perroco; Maira O Oliveira; Rafael F Nunes; Toulouse Leusin Pinheiro; Cassio M C Bottino; Claudia C Leite; Carlos A Buchpiguel Journal: Dement Neuropsychol Date: 2015 Oct-Dec
Authors: Melissa Scholefield; Stephanie J Church; Jingshu Xu; Andrew C Robinson; Natalie J Gardiner; Federico Roncaroli; Nigel M Hooper; Richard D Unwin; Garth J S Cooper Journal: Metabolites Date: 2020-10-29
Authors: Se Jong Oh; Namhun Lee; Kyung Rok Nam; Kyung Jun Kang; Sang Jin Han; Kyo Chul Lee; Yong Jin Lee; Jae Yong Choi Journal: Front Neurosci Date: 2022-08-05 Impact factor: 5.152